" class="no-js "lang="en-US"> Faz Chowdhury - Medtech Alert
Thursday, September 04, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Faz Chowdhury

Faz Chowdhury

About Faz Chowdhury

Dr. Chowdhury has served as CEO and Chairman of the Board of Nemaura Medical Inc. since 2013. He has over 20 years of experience in the Pharmaceutical and Medical devices industry, taking products from concept to commercial launch. He is sole inventor on more than 100 granted and pending patents across 15 technology platforms within the medical device and pharmaceutical sectors and has authored Textbook Chapters on Nano-biosciences for Wiley and Elsevier. Dr. Chowdhury is a regular speaker at international conferences in this field and serves on the Board of Medilink East Midlands, UK. He holds a Masters in Microsystems and Nanotechnology from Cranfield University, UK, and a Doctorate from the University of Oxford on nano-medicine and drug delivery.

Related Story

Diseases

 Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S. | Pharmtech Focus|Nemaura and EverEVERSANA Sign Preliminary Agreement for Large-scale Launch of Nemaura’s Diabetes Management Program in the U.S. | Pharmtech Focus

Nemaura and EVERSANA sign preliminary agreement for large-scale launch of Nemaura’s Diabetes Management Program in the U.S.

September 28 2022

Nemaura Medical, Inc.(NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and […]